Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1148 articles about Moderna, Inc.
-
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
-
Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020
2/12/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2020 to report its fourth quarter and full year 2019 financial results,
-
Moderna Announces Pricing of Public Offering of Shares of Common Stock - Feb. 12, 2020
2/12/2020
Moderna, Inc. announced the pricing of an underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions.
-
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.
-
Moderna Announces Proposed Public Offering of Shares of Common Stock
2/10/2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has commenced an underwritten public offering of $500 million in shares of common stock.
-
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates
2/10/2020
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.
-
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
2/10/2020
Moderna, Inc. announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of escalating doses of mRNA-3704 administered via intravenous infusion in patients with isolated methylmalonic acidemia due to MUT deficiency.
-
China Coronavirus Update: Continued Spread, Run on Antivirals and Facemasks, Baby Diagnosed
2/6/2020
The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagn... -
Sandra Horning, M.D. To Join Moderna’s Board of Directors
2/3/2020
Former Genentech/Roche Chief Medical Officer and Head of Global Product Development will bring extensive global biopharma expertise to support Moderna’s late-stage development efforts
-
The spreading of the coronavirus that began in Wuhan, China has researchers and health officials worldwide studying the emerging virus and preparing to treat it and develop vaccines. With such an enormous global focus, it seems that new information about the virus and the infection is being publi...
-
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
1/30/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Melanie Ivarsson, Ph.D., M.B.A., will join the company as its Chief Development Officer
-
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
-
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus
1/23/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the Coalition for Epidemic Preparedness Innovations (CEPI), today announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).
-
The new coronavirus infection appears connected to a seafood market in Wuhan City in China, which has more a population of more than 11 million.
-
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
-
The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
1/12/2020
mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases
-
Moderna Sees Potential Blockbuster in Investigational Vaccine for Disease That Can Cause Birth De...
1/10/2020
Moderna Therapeutics is inching closer to becoming a commercial company and the company sees a potential blockbuster in an experimental treatment. -
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
1/9/2020
Phase 2 interim data at three months, expected in 2H 2020, intended to inform Phase 3 dose selection